Bux Pain Management Launches SynchroMed III Pain Pump

Bux Pain Management, based in Lexington, KY, announced the introduction of the SynchroMed III intrathecal drug delivery system into their practice. The innovative system, designed for individuals with chronic pain, cancer pain, and severe spasticity, received FDA approval on October 10, 2023. This development highlights Bux Pain Management's dedication to providing advanced and efficacious care.

The SynchroMed III, developed by Medtronic, upgrades pain management with its enhanced safety, efficiency, and the ability to directly administer medication into the spinal fluid. It features significant improvements like a "refill only" workflow and updatable firmware post-implantation. Dr. Anjum Bux, with 18 years of experience and nearly 500 intrathecal pain pump implants, was among the first to adopt this technology. The first recipient in Kentucky has experienced considerable improvements in quality of life, including the ability to participate in activities previously hindered by pain.

Dr. Bux emphasizes the device's role in advancing chronic pain management, offering a significant reduction in side effects compared to traditional methods. Amid the opioid crisis, the SynchroMed III system presents a viable alternative, providing precise medication delivery and compatibility with MRI scans. Dr. Bux has already implanted 20 SynchroMed III pumps, managing a total of approximately 700 pain pumps, reaffirming his commitment to improving patient outcomes.